Document is current

Any future updates will be listed below

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of sacituzumab govitecan for breast cancer, fruquintinib for colorectal cancer, amivantamab for lung cancer, repotrectinib for lung cancer, tasurgratinib for biliary tract cancer, enfortumab vedotin plus pembrolizumab for urothelial cancer, and dabrafenib plus trametinib for glioma in Japan

Crossref DOI link: https://doi.org/10.1007/s10147-024-02644-7

Published Online: 2024-10-14

Published Print: 2024-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark